U.S., July 21 -- ClinicalTrials.gov registry received information related to the study (NCT07714863) titled 'ML-Based ABPA Recurrence Prediction and Clinical Utility' on July 08.
Brief Summary: This multicenter bidirectional cohort study aims to develop and externally validate a machine learning model for predicting the risk of acute exacerbation within 1 year in patients with allergic bronchopulmonary aspergillosis (ABPA) during the stable phase, and further to evaluate the model's practical value in risk stratification and clinical decision-making.
All patients diagnosed with ABPA according to the ISHAM 2024 criteria will be assigned to either the acute exacerbation group or the non-exacerbation group based on whether they experience an...